Cargando…
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
BACKGROUND: Low Density Lipoprotein (LDL) hypercholesterolemia, and its associated cardiovascular diseases, are some of the leading causes of death worldwide. The ability of proprotein convertase subtilisin/kexin 9 (PCSK9) to modulate circulating LDL cholesterol (LDLc) concentrations made it a very...
Autores principales: | Galabova, Gergana, Brunner, Sylvia, Winsauer, Gabriele, Juno, Claudia, Wanko, Bettina, Mairhofer, Andreas, Lührs, Petra, Schneeberger, Achim, von Bonin, Arne, Mattner, Frank, Schmidt, Walter, Staffler, Guenther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256444/ https://www.ncbi.nlm.nih.gov/pubmed/25474576 http://dx.doi.org/10.1371/journal.pone.0114469 |
Ejemplares similares
-
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
por: Zeitlinger, Markus, et al.
Publicado: (2021) -
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
por: Meissner, Wassilios G., et al.
Publicado: (2020) -
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
por: Landlinger, Christine, et al.
Publicado: (2017) -
Evaluation of (sdLDLc*HCYc)/HDLc ratio in clinical auxiliary diagnosis of primary cerebral infarction
por: Luo, Chunhua, et al.
Publicado: (2022) -
LDLC encodes a brefeldin A-sensitive, peripheral Golgi protein required for normal Golgi function
Publicado: (1994)